Rahila Bilal, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 20 Hartford St, Houlton, ME 04730 Phone: 207-532-2900 Fax: 207-532-5974 |
News Archive
The Wall Street Journal reports on this trend. Meanwhile, other news outlets report on state-specific developments regarding the debates over expanding the health program for low-income people.
PhotoMedex, Inc. announced that the Company has received from AMICO Group, its distributor in the Middle East, a multi-million dollar order to purchase XTRAC laser systems that will be installed in hospitals throughout the Kingdom of Saudi Arabia. The order includes customary terms and conditions, including advanced payments and letters of credit covering the purchase order. Delivery is expected to be in the third and fourth quarters of this year.
Conventional biological wisdom holds that living cells interact with their environment through an elaborate network of chemical signals. As a result many therapies for the treatment of cancer and other diseases in which cell behavior goes awry focus on drugs that block or disrupt harmful chemical signals.
Stem cells are ideal tools to understand disease and develop new treatments; however, they can be difficult to obtain in necessary quantities. In particular, generating induced pluripotent stem (iPS) cells can be an arduous task because reprogramming differentiated adult skin cells into iPS cells requires many steps and the efficiency is very low - researchers might end up with only a few iPS cells even if they started with a million skin cells.
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced completion of patient enrollment in the company's two ongoing Phase III clinical trials studying eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome, or IBS-d. Both studies met their target enrollments and Furiex expects to release top line results in the first quarter of 2014.
› Verified 2 days ago